Rheumatologists typically manage systemic autoimmune rheumatic diseases (SARD) and associated interstitial lung disease (ILD) with immunosuppressants. However, evidence increasingly supports also the use of antifibrotic agents in this setting. Pulmonologists have long used antifibrotics for ILD caused by idiopathic pulmonary fibrosis (IPF) and other conditions, but rheumatologists have limited experience with these drugs.